SMTG contemplates a respite

SMTG contemplates a respite

When Somatogen Inc. proposed its $40 million offering in August, BioCentury estimated the company would need an additional $170 million for operations and facilities through 1997 and product launch of its rHb1.1 recombinant blood substitute.

Since then, according to CFO Timothy Hoogheem, the company has cut its burn rate

Read the full 527 word article

How to gain access

Continue reading with a
two-week free trial.